deaths (OS)progression or deaths (PFS)RFS/DFS

mUC - M - PDL1 positive metastatic/advanced UC (mUC) - maintenance (M) mUC - M - PDL1 positive

versus BSC
avelumab alone vs. BSC 1 certainty unassessablestatistically conclusive-40% certainty unassessable-40%-